Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 24 Apr 2017 Planned End Date changed from 1 Jun 2019 to 1 Apr 2019.
- 24 Apr 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Apr 2019.
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.